Compare AIRI & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | CODX |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | AIRI | CODX |
|---|---|---|
| Price | $2.88 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 27.5K | ★ 1.6M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,031,000.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $0.23 |
| 52 Week High | $4.70 | $1.55 |
| Indicator | AIRI | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 38.66 |
| Support Level | $2.95 | $0.34 |
| Resistance Level | $3.15 | $0.41 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 14.26 | 0.28 |
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.